Open access

801 PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients
Erika Hamilton, Sarah Nikiforow, Philip Bardwell, Christine McInnis, Jeffrey Zhang, George Blumenschein, Mihaela Cristea, Keren Osman, Anthony Shields, Marlyane Motta, Sanela Bilic, Oliver Schoenborn-Kellenberger, James Rakestraw, Shawn Carey, Elena Geretti, Karsten Sauer, Tim Harris, Tap Maniar, Becker Hewes, Thomas Andresen, Jonathan Fitzgerald, Harriet Kluger

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A479-A480; DOI: 10.1136/jitc-2020-SITC2020.0801
78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
Dingwei Ye, Aiping Zhou, Qing Zou, Hanzhong Li, Cheng Fu, Hailong Hu, Jian Huang, Wei Shen, Yun Zhang, Xiaopeng Ma, Pei Zhang, Ruiqi Huang, Xiusong Qiu, Lilin Zhang, Feng Bi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A48-A49; DOI: 10.1136/jitc-2020-SITC2020.0078
803 Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors
Sumayah Jamal, Adnan Nagrial, Anthony Joshua, Richard Eek, Sumayah Jamal

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A480-A481; DOI: 10.1136/jitc-2020-SITC2020.0803
804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
Xiaozhong Chen, Wei Wang, Qingfeng Zou, Jingao Li, Chaosu Hu, Chaosu Hu, Qin Lin, Xiaodong Zhu, Yi Jiang, Yan Sun, Liangfang Shen, Lin Wang, Guorong Zou, Xiaoyan Lin, Ying Wang, Shaojun Lin, Minying Li, Rui Ao, Ruilian Xu, Haifeng Lin, Rensheng Wang, Jiacheng Yang, Weifeng Song, Max Wang, Baiyong Li, Yu Xia

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A481; DOI: 10.1136/jitc-2020-SITC2020.0804
816 Evaluating the potential of harnessing anti-leukemia T cells for the treatment of T cell acute lymphoblastic leukemias (T-ALL)
Todd Triplett, Sarah Church, Tyler Hether, Joshua Rios, Srividya Kottapalli, Nisha Holay

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A487-A488; DOI: 10.1136/jitc-2020-SITC2020.0816
814 MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity
Kees Bol, Wilfred Marissen, Jeroen Elaissais-Schaap, Paul Tacken, Steef Engels, Liang-Chuan Wang, Arpita Mondal, Mark Throsby, Alan Roberts, Patrick Mayes, Cecile Geuijen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A487; DOI: 10.1136/jitc-2020-SITC2020.0814
818 Synergistic cancer immunotherapy using tumor tissue-derived exosomes and artificially produced bacterial outer membrane vesicles
Kyong-su Park, Jan Lötvall, Kristina Svennerholm, Rossella Crescitelli, Cecilia Lässer, Inta Gribonika

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A488-A489; DOI: 10.1136/jitc-2020-SITC2020.0818
821 Class specific HDAC inhibition differentially affects the function of specific T cell subsets
Nisha Holay, Uma Giri, Carla Van Den Berg, Gail Eckhardt, Todd Triplett

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A491-A492; DOI: 10.1136/jitc-2020-SITC2020.0821
823 CD4 T cells are essential for an anti-tumor effect in a B78 murine melanoma tumor model
Arika Feils, Mackenzie Heck, Anna Hoefges, Peter Carlson, Luke Zangl, Ravi Patel, Dmitriy Kravtsov, Jacquelyn Hank, Zachary Morris, Alexander Rakhmilevich, Paul Sondel, Amy Erbe

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A492; DOI: 10.1136/jitc-2020-SITC2020.0823
825 Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients
Denise Goh, Chun Chau Lawrence Cheung, Xinru Lim, Tracy Zhijun Tien, Jeffrey Chun Tatt Lim, Sanjna Nilesh Nerurkar, Loong Shihleone, Peng Chung Cheow, Chung Yip Chan, Ye Xin Koh, Thuan Tong Tan, Shirin Kalimuddin, Wai Meng David Tai, Jia Lin Ng, Jenny Guek-Hong Low, Joe Poh Sheng Yeong, Tony Kiat Hon Lim

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A493-A494; DOI: 10.1136/jitc-2020-SITC2020.0825

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages